NeuroPrecision Lab

🚨Our stratified analysis published @JNNP_BMJ (4,548 stroke admissions) across 4 hubs + 60 spokes shows that an AI-driven triage platform improved workflow and increased EVT utilization with remarkable cost savings! @PittStroke @PittNeurology 🔗 jnnp.bmj.com/content/early/…

An insightful presentation and discussion points by @RaulNogueiraMD on MeVOs and the art of trial design during NIH STEP webinar! @PittStroke @PittNeurology

“Hospitals treat efficiently once patients arrive, yet many patients lose critical hours before they reach them” Please read our editorial on ICH reversal and system of care fragmentation 🔗 ahajournals.org/doi/10.1161/JA… Thanks for the invitation @OmarAlJanabiMD @Mo_majali91

A great win for our field with the presentation of ORIENTAL MeVO — the first trial on moderate to severe MeVO (median NIHSS=10). The study opens the door for future adaptive research. Presented by our own @RaulNogueiraMD at #ISC26. @PittStroke

Happy to present our DUSK tool to individualize treatment for distal medium vessel occlusion! Time to move beyond “one-size-fits-all”@PittStroke @PittNeurology @NeuroprecisionL

Pleased to present our work on multidimensional clot characterization and the need for real time assessment and dynamic evaluation for optimizing first line technique and procedural outcomes! @PittStroke @PittNeurology @NeuroprecisionL

From “Does EVT work for DMVO?”❌ to "WHICH patients benefit most?" ✅, we used explainable counterfactual model to move beyond "one-size-fits-all".🧐 🔗 onlinelibrary.wiley.com/doi/10.1002/an… 🔗 dusktool.streamlit.app @ANA_journals @NeuroprecisionL @PittStroke @PittNeurology @RaulNogueiraMD

@RaulNogueiraMD presenting on “Intra-Arterial Nano-Thrombolysis in Stroke” at the Brain meeting in London.

Happy to share two new co-authored multicenter publications on tenecteplase vs alteplase in BAO patients undergoing EVT, with contributions from @PittStroke and @NeuroprecisionL 🔗 onlinelibrary.wiley.com/doi/10.1002/an… 🔗 onlinelibrary.wiley.com/doi/10.1002/ac…

Contact aspiration’s first-pass benefits seemingly “offset” by inferior final recanalisation versus stent retrievers in basilar occlusion stroke 🔗 neuronewsinternational.com/contact-aspira… @RaulNogueiraMD @PittStroke @PittNeurology

🚨 New from the VERITAS collaboration: Bridging IVT→EVT in basilar artery occlusion is safe but shows no added benefit vs EVT alone which establish equipoise. Findings from pooled 4 RCTs support tailored decision-making in VBAO strokes. @PittStroke 🔗 link.springer.com/article/10.100…

#WSC2025 #IAT_TOP 🌐 Multicenter RCT 🇨🇳n=246 💉 IA-tPA 0.225 mg/kg vs standard care after eTICI ≥ 2b50 in posterior AIS 🎯 mRS 0–2 at 90d: 🟡41.9% vs 46.7% (NS) ⚠️ sICH ≈ 2.5%, no excess risk ➡️ No functional benefit of adjunct IA-tPA after EVT in PC stroke @RaulNogueiraMD

Our @RaulNogueiraMD in Opening & Closing Plenaries! 🧠 1️⃣ #ANGEL_COAST: BAO<24h → ↑CA, ↑FPE, ↓complete recan, no clinical difference. 2️⃣ #IAT_TOP: mRS 0–2 @90d 41.9% vs 46.7% (NS) but safe. 3️⃣ HEMERA-1: #PP_007 shows promise vs matched @PittStroke @fahmy_doheim @PittNeurology

🧠PEARL RCT co-authored by @RaulNogueiraMD: IA alteplase after thrombectomy → better recovery (mRS 0-1: 45% vs 30%) w/o ↑ bleeding. 🔗tinyurl.com/5hczvc4r ✅ Matches our pooled analysis on IAT post-EVT. 🔗 tinyurl.com/mususm69 @fahmy_doheim @PittStroke #NeuroTwitter